{"id":"peg-ifn-2a","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/psychiatric effects"},{"rate":"5-15","effect":"Thyroid dysfunction"},{"rate":"10-20","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL405705","moleculeType":"Small molecule","molecularWeight":"1256.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peg-IFNα-2a is a pegylated form of interferon alpha-2a that extends the drug's half-life and duration of action. It binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral genes, enhance natural killer cell activity, and promote apoptosis in infected or malignant cells. The pegylation allows for less frequent dosing while maintaining therapeutic efficacy.","oneSentence":"Pegylated interferon alpha-2a activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:11.368Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"},{"name":"Certain malignancies (e.g., melanoma, some hematologic cancers)"}]},"trialDetails":[{"nctId":"NCT04980482","phase":"PHASE2","title":"Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-10-29","conditions":"Chronic Hepatitis b","enrollment":43},{"nctId":"NCT02021643","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-12-10","conditions":"Chronic HCV Infection","enrollment":687},{"nctId":"NCT01318694","phase":"PHASE3","title":"Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2011-03","conditions":"Hepatitis C","enrollment":1081},{"nctId":"NCT01215643","phase":"PHASE2","title":"Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2010-10","conditions":"Hepatitis C, Chronic Pain","enrollment":340},{"nctId":"NCT01500772","phase":"PHASE3","title":"Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2012-03","conditions":"Hepatitis C","enrollment":6},{"nctId":"NCT01258101","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-05","conditions":"Hepatitis C, Chronic","enrollment":395},{"nctId":"NCT01970904","phase":"NA","title":"Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2013-10","conditions":"Hepatitis C, Liver Disease","enrollment":147},{"nctId":"NCT00537407","phase":"PHASE2","title":"A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2007-09","conditions":"Chronic Hepatitis C","enrollment":50},{"nctId":"NCT00854802","phase":"NA","title":"A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2009-01","conditions":"Chronic Hepatitis C","enrollment":290},{"nctId":"NCT01906580","phase":"PHASE4","title":"Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2011-07","conditions":"Chronic Hepatitis B","enrollment":105},{"nctId":"NCT00395421","phase":"PHASE2","title":"Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":"Chronic Hepatitis C","enrollment":114},{"nctId":"NCT00158522","phase":"PHASE3","title":"Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2003-02","conditions":"Hepatitis C","enrollment":31},{"nctId":"NCT00158496","phase":"PHASE3","title":"Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2002-08","conditions":"Chronic Hepatitis C","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":108,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["peginterferon alfa-2a","pegylated interferon alpha 2a"],"phase":"marketed","status":"active","brandName":"Peg-IFNα-2a","genericName":"Peg-IFNα-2a","companyName":"Beijing 302 Hospital","companyId":"beijing-302-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alpha-2a activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity. Used for Chronic hepatitis B, Chronic hepatitis C, Certain malignancies (e.g., melanoma, some hematologic cancers).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}